SEARCH

SEARCH BY CITATION

References

  • 1
    Cammà C, Giunta M, Pinzello GB, Morabito A, Verderio P, Pagliaro L. Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of randomized controlled trials. Am J Gastroenterol 1999; 94:581595. MEDLINE
  • 2
    Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, et al. for the International Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339:14931499. MEDLINE
  • 3
    Chow WC, Boyer N, Pouteau M, Castelnau C, Martinot-Peignoux M, Martins-Amado V, Degos F, et al. Re-treatment with interferon alfa of patients with chronic hepatitis C. Hepatology 1998; 27:11441148. MEDLINE
  • 4
    Chemello L, Cavalletto L, Donada C, Bonetti P, Casarin P, Urban F, Bernardinello E, et al. Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. Gastroenterology 1997; 113:16541659. MEDLINE
  • 5
    Heathcote EJL, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, Albert DG, et al. and the Consensus Interferon Study Group. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998; 27:11361143. MEDLINE
  • 6
    Almasio PL, Di Marco V, Bonura C, Fuschi P, Cammà C, Lo Iacono O, Artini M, et al. Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon. Dig Dis Sci 1999; 44:10131019. MEDLINE
  • 7
    Picciotto A, Brizzolara R, Campo N, Poggi G, Sinelli N, DeConca V, Giudici-Cipriani A. Two year interferon retreatment may induce a sustained response in relapsing patients with chronic hepatitis C [Abstact]. Hepatology 24(Suppl): 10131019.
  • 8
    Payen JL, Izopet J, Galindo-Migeot V, Lauwers-Cances V, Zarski JP, Seigneurin JM, Dussaix E, et al. and le Groupe d'etude et de traitement du virus de l'hepatitie C. Better efficacy of a 12-months interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-months treatment: a multicenter, controlled, randomized trial. Hepatology 1998; 28:16801686. MEDLINE
  • 9
    Toyoda H, Nakano S, Takeda I, Kumada T, Sugiyama K, Osama T, Kiriyama S. Retreatment of chronic hepatitis C with interferon. Am J Gastroenterol 1994; 89:14531457. MEDLINE
  • 10
    Weiland O, Zhang YY, Widell A. Serum HCV-RNA levels in patients with chronic hepatitis C given a second course of interferon alpha-2b treatment after relapse following initial treatment. Scand J Infect Dis 1993; 25:2530. MEDLINE
  • 11
    Pardo M, Coronat T, Herrero M, Marriott E, Artillo S, Quiroga JA, Carreño V. Retreatment of chronic hepatitis C virus infection. Lancet 1994; 343:15681569. MEDLINE
  • 12
    Horiike N, Kurose K, Ohkura I, Masumoto T, Nakanishi K, Michitaka K, Onji M. Retreatment with interferon in chronic hepatitis C [Abstract]. J Hepatol 1994; 21:1155. MEDLINE
  • 13
    Iaquinto G, Ambrosone L, De Vita A, Masucci F, Rambaldi M. Response to retreatment with alfa interferon in relapsed and non responder patients [Abstract]. J Hepatol 1995; 23(Suppl):194.
  • 14
    Bonkowsky HL, Clifford BD, Smith LJ, Allan C, Banner B. High-dose interferon-alpha-2b for retreatment of non-responders or relapsing patients with chronic hepatitis C: a controlled randomized trial. Dig Dis Sci 1996; 41:149154. MEDLINE
  • 15
    Le X, Zhou X, Dai X. Evaluation of interferon alpha for the treatment of relapsed hepatitis C [Abstract]. Hepatology 1996; 24(Suppl):536A.
  • 16
    Gerken G, Teuber G, Goergen B, Meyer zum Buschenfelde KH. Interferon-alpha retreatment in chronic hepatitis C. J Hepatol 1995; 22(Suppl):118121. MEDLINE
  • 17
    Kakumu S, Yoshioka K. Retreatment with interferon in patients with chronic hepatitis C [letter]. J Hepatol 21: 118121.
  • 18
    Marriott E, Quiroga JA, Carreño V. Retreatment of chronic hepatitis C with interferon-α. J Infect Dis 1992; 166:12001201. MEDLINE
  • 19
    Bresci G, Parisi G, Banti S, Capzia A. Re-treatment of interferon-resistant patients with chronic hepatitis C with interferon-α. J Viral Hepat 1995; 2:155158. MEDLINE
  • 20
    d'Aquino M, Tempesta D, Bibiani S, Vianello G, Pipan C, Bellati G, Colloredo G. Chronic hepatitis C: an analysis of factors which influence the responce to interferon therapy proven to be useful to optimize a second course [Abstract]. Hepatology 1996; 24(Suppl):498A.
  • 21
    Hagiwara H, Hayashi N, Oshita M, Katayama K, Kasahara A, Fusamoto H, Kamada T. Retreatment with 24-week course of interferon-alpha for patients with chronic hepatitis C. Int Hepatol Commun 1996; 5:135142.
  • 22
    Alberti A, Chemello L, Noventa F, Cavalletto L, De Salvo GL. Therapy of hepatitis C: re-treatment with alpha interferon. Hepatology 1997; 26(Suppl):137S142S. MEDLINE
  • 23
    Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74:10931203. MEDLINE
  • 24
    Lindsay KL. Therapy of chronic hepatitis C: overview. Hepatology 1997; 26(Suppl):71S77S. MEDLINE
  • 25
    Pagliaro L, Craxì A, Cammá C, Tinè F, Di Marco V, Lo Iacono O, Almasio P. Interferon-α for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 1994; 19:820828. MEDLINE
  • 26
    SAS Technical Report. SAS/STAT Software: Changes & Enhancements, Release 6.07. Cary, NC: SAS Institute Inc. 1992.
  • 27
    Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143:2936. MEDLINE
  • 28
    Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curve derived from the same cases. Radiology 1983; 148:839843. MEDLINE
  • 29
    Hayashi J, Kawakami Y, Nabeshima A, Kishihara Y, Furusyo N, Sawayama Y, Kinukawa N, et al. Comparison of HCV RNA levels by branched DNA probe assay and by competitive polymerase chain reaction to predict effectiveness of interferon treatment for patients with chronic hepatitis C virus. Dig Dis Sci 1998; 43:384391. MEDLINE
  • 30
    Lu RH, Hwang SJ, Chan CY, Chang FY, Lee SD. Quantitative measurement of serum HCV RNA in patients with chronic hepatitis C: comparison between Amplicor HCV Monitor system and branched DNA signal amplification assay. J Clin Lab Anal 1998; 12:121125. MEDLINE
  • 31
    Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnerborg A, Weiland O. Comparison of 3 quantitative HCV RNA assays–accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C. Scand J Infect Dis 1998; 30:441446. MEDLINE
  • 32
    Bruno S, Manzin A, Bellati G, Crosignani A, Borzio M, Battezzati PM, Maggioni M, et al. Posttreatment natural history of subjects with chronic hepatitis C (CHC) showing sustained biochemical response (SR) to interferon-α (IFN) therapy [Abstract]. Hepatology 1998; 28(Suppl):578A.
  • 33
    Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, Murray-Lyon I, et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998; 46:563570. MEDLINE
  • 34
    Tappero G, Ballaré M, Farina M, Negro F. Severe anemia following combined–interferon/ribavirin therapy of chronic hepatitis C. J Hepatol 1998; 29:10331034. MEDLINE
  • 35
    Bergmann JF. Opinion on interferon-ribavirin association for the first-intention treatment of chronic hepatitis C. Presse Med 1999; 28:7778. MEDLINE